MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Globe Newswire•10/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.